Scholar Rock Holding stock has delivered an exceptionally strong run over the past few years, yet its valuation checks currently lean expensive rather than cheap. After such a move, investors are weighing robust momentum against signals that the shares may already reflect a lot of optimism.

• Scholar Rock Holding has returned very roughly 8x over the last 3 years, which puts extra focus on whether recent gains are supported by fundamentals.
• The progress on apitegromab, including the removal of the non compliant Catalent Indiana facility from its Biologics License Application and a clear regulatory path ahead, can support growth expectations, while any setback around approval or launch execution may weigh heavily on what investors are willing to pay.
• The stock scores 2 out of 6 on the broader valuation checks, which suggests Scholar Rock Holding does not screen as a clear bargain overall and leans on the expensive side based on this framework 2/6.

The issue now is whether Scholar Rock Holding's current share price still offers an attractive entry after such a strong run or whether it already prices in most of the good news.

Does Scholar Rock Holding Look Pricey on Book Value?

The P/B ratio is a useful cross check for Scholar Rock Holding because the stock is still in the loss making stage, so earnings based multiples are less helpful.

Scholar Rock Holding currently trades on a P/B of 27.1x. That is far above the wider biotech industry average of 2.5x and also well above the peer group average of 9.6x. This gap indicates investors are paying a very rich price relative to the company’s current equity base.

Recent progress around apitegromab and the cleaned up regulatory path help explain why sentiment is strong. However, the current P/B still prices Scholar Rock Holding at a premium that the sector benchmarks do not support. On this framework the stock screens as clearly overvalued on book value compared with both its industry and closer peers.

On the P/B multiple, Scholar Rock Holding stock looks overvalued compared with both the biotech industry and its peer group.

The Scholar Rock Holding Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Scholar Rock Holding pick up where the P/B puzzle leaves off and explain what kind of growth, margins and earnings path would need to occur for the stock to be worth significantly more or less than it is today on the market. Instead of a single ratio or model output, they describe the future that number depends on so you can track whether Scholar Rock Holding's actual progress aligns with those assumptions over time.

Be one of the first voices in the Simply Wall St community to set out a clear, number driven narrative on whether Scholar Rock Holding's progress with apitegromab and its updated regulatory path really supports today's price. Share your view now and track how Scholar Rock Holding's story and valuation case hold up as fresh results and regulatory milestones arrive.

Do you think there's more to the story for Scholar Rock Holding? Head over to our Community to see what others are saying!

The Bottom Line

Scholar Rock Holding now trades on market multiples that screen as clearly overvalued, especially against both the broader biotech group and closer peers. That premium leans heavily on confidence in apitegromab's regulatory path and eventual commercial execution. For current and prospective holders, the key question is whether future trial, approval and launch outcomes ultimately justify that rich multiple or whether expectations need to cool from here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.